Viral Vectors

News Viral Vectors

• Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo with Enhanced Novel MicroRNA AAV Gene Therapy

  Amsterdam Molecular Therapeutics (AMT) Holding N.V. announced that its gene therapy product incorporating siRNA sequences into microRNA scaffolds to silence Apolipoprotein B100 (AAV-miApoB) was able to significantly lower plasma cholesterol levels in vivo over a period of 18 weeks. These preliminary more

• Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo with Enhanced Novel MicroRNA AAV Gene Therapy

  Amsterdam Molecular Therapeutics (AMT) Holding N.V. announced that its gene therapy product incorporating siRNA sequences into microRNA scaffolds to silence Apolipoprotein B100 (AAV-miApoB) was able to significantly lower plasma cholesterol levels in vivo over a period of 18 weeks. These preliminary more

• AMT receives orphan drug designation from the U.S. Food and Drug Administration Duchenne Muscular Dystrophy gene therapy

  Amsterdam Molecular Therapeutics (AMT) Holding N.V. announced that the U.S. Food and Drug Administration (FDA) has designated AMT-080, a gene therapy for Duchenne muscular dystrophy (DMD) as an orphan drug. In October 2009, the Committee for Orphan Medical Products of the European Medicines Agency g more

White papers Viral Vectors

• Fugene® HD Transfection Reagent: Superior Performance for Challenging Expression Studies
  

  The ability to efficiently introduce foreign molecules into cells constitutes an important tool in any laboratory and facilitates studies of gene regulation and protein function. A plethora of transfection methods have been developed for transfer of DNA into mammalian and animal cells. Those methods either utilize the physicochemical properties of the vector-carrier of the DNA or use mammalian viruses. In the first group of methods, some classic techniques are well-known, such as: calcium phosphate, DEAE-dextran, electroporation liposome-mediated delivery, direct microinjection/biolistic particle delivery, and non-liposomal multi-component reagents. Viral vector systems use both DNA (Adeno-) and RNA (Retro-, Lenti-) viruses. more

• HelpCorner - Gene Silencing
  

  more

• HelpCorner - Transfection
  

  Transfection is the delivery of DNA, RNA, proteins, and macromelecules into eukaryotic cells. The goals for transfection include the study of gene function and regulation as well as protein expression and function. It is also used for gene silencing and protein production. According to the application, the information can be either transiently (transient transfection) or permanently expressed (stable transfection). Based on the strategies, the transfection methods can be divided into three groups: more

Publications Viral Vectors

• Mechanism for the endocytosis of spherical nucleic acid nanoparticle conjugates [Applied Biological Sciences]

  Intracellular delivery of nucleic acids as gene regulation agents typically requires the use of cationic carriers or viral vectors, yet issues related to cellular toxicity or immune responses hamper their attractiveness as therapeutic candidates. The discovery that spherical nucleic acids (SNAs), po more

• LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus [Cell Biology]

  Vesicular stomatitis virus (VSV) exhibits a remarkably robust and pantropic infectivity, mediated by its coat protein, VSV-G. Using this property, recombinant forms of VSV and VSV-G-pseudotyped viral vectors are being developed for gene therapy, vaccination, and viral oncolysis and are extensively u more

• Evaluation of cell‐penetrating peptide/adenovirus particles for transduction of CAR‐negative cells

  Abstract Adenovirus (Ad) is a promising gene therapy vector, and is used currently in more than 23% of clinical gene therapy trials. The viral vector, however, has drawbacks such as immunogenicity, promiscuous tropism, and the inability to infect certain types of cells. The focus of this work wa more

Market studies Viral Vectors

• ReGenX Biosciences, LLC - Strategic SWOT Analysis Review

  ReGenX Biosciences, LLC (ReGenX) is a bio pharmaceutical company that is engaged in research and development of therapeutics based on adeno-associated viral vectors (AAV vectors). These vectors offer a platform for targeting diseases caused by genetic errors based on a natural phenomenon that effici more

• Worldwide Biotech & Pharmaceutical Co. (WWBP) - Financial and Strategic SWOT Analysis Review

  Worldwide Biotech & Pharmaceutical Company (WWBP) is a pharmaceutical company engaged in developing and marketing of viruses and viral vectors. The company is also into development of external diagnostic reagents, prophylactic vaccines for humans, oral solid dosage and hepatitis C vaccine. It intend more

• Transgene SA (TNG) - Financial and Strategic SWOT Analysis Review

  Transgene SA (Transgene) is a publicly held bio pharmaceutical company engaged in the discovery and development of gene-based therapeutic vaccines and immunotherapy products used to treat cancer and infectious diseases. The company develops vaccines and products in specific indications and maintains more

Websites Viral Vectors